Sunday 18 October 2026
Export QTTB’s income statement to Excel — free account
Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.52
0.25
−3.22%
Follow QTTB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.41 | 4.26 | 4.76 | 19.68 | |
Current Ratio |
4.57 | 4.85 | 5.36 | 20.30 | |
Net Debt/EBITDA |
5.08 | 4.99 | 5.60 | 11.68 | |
Debt/Assets |
19.44% | 15.71% | 12.84% | 0.00% | |
Debt/Equity |
(0.61) | 0.23 | 0.18 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.57 | (0.11) | 0.83 | 0.34 | |
Capex/Depreciation |
0.00 | 55.12 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.50) | (0.45) | (0.15) | |
Capex per Share |
0.00 | 0.57 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.35) | 0.07 | (0.45) | (0.15) | |
Cash per Share |
4.01 | 3.93 | 3.60 | 5.22 | |
Shareholders Equity per Share |
(1.51) | 3.42 | 3.29 | 5.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.51) | 3.42 | 3.29 | 5.21 | |
Free Cash Flow |
(4.23) | 0.82 | (6.34) | (3.07) | |
Working Capital |
39.70 | 43.70 | 46.53 | 104.25 | |
Capital Expenditures |
— | 7.00 | — | — | |
Net Current Asset Value |
(25.42) | 35.29 | 39.84 | 99.68 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
1.12 | 1.93 | 1.68 | 1.24 | |
Average Assets |
81.16 | 77.05 | 71.37 | 90.99 | |
Average Common Equity |
(0.08) | 23.84 | 21.15 | 46.84 |
Columns are period end dates